Alan Young

American Oriental: Established Pharma with Large, Steady Free Cash Flow

No reason to believe the stock will become more valuable as long as management is still using the same decision-making process they used last year to allocate capital for acquisitions.

IOW, free cash flow doesn't do much good if management decides to encumber it with more acquisitions.

It may be a fine company in the long run, but at this point, "show me".

In the Bargain Bin: American Oriental Bioengineering

I liked AOB as a niche player last year. They got a lot of cash and started acquiring numerous small companies with it. I wanted a medicine-seller bringing value to shareholders, not an empire-builder trying to expand the balance sheet exponentially, so I dropped out--along with many other investors. That's why the stock has been unpopular.

Chinese medicine is hard enough to understand; Chinese small-business acquisition and real estate deals make it too complicated.
I wish them well, but this stock is not for me.

American Oriental Investors Remain Wary Despite Impressive Q4

You have hit the nail on the head. I thought AOB was a great little company when it was a small niche player. When it turned to empire-building, I bailed.